drugset / Trial / NCT03736330

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

NCT03736330

Phase 2 Unknown 24 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Phase II clinical trial to investigate the safety, clinical activity and toxicity of combinations of D-CIK and low dose anti-PD-1 antibody in patients with metastatic renal cell carcinoma treated with axitinib.

Timeline

Start
2018-09-08
Primary completion
2020-10-08
Completion
2021-11-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral
Subject D-CIK Cell therapy 1e+10 cells Intravenous
Subject D-CIK Cell therapy 1.5e+10 cells Intravenous
Subject Pembrolizumab Monoclonal antibody

Indications